Is Aptinyx (NASDAQ:APTX) Stock A Good Value Buying Below $3?
7:51 pm Friday, July 16th, 2021
Investors are almost always interested in the biotech sector due to the sort of advancement that have been made by different biotech companies and one of the companies that could be tracked at this point is Aptinyx (NASDAQ:APTX). Experts believe that it could be a company worth following due to its work in relation to NMDA receptors.
That is the only thing on which the company is focussed at this point in time. These receptors help with the synapses and this particular function is important since it can help individuals with memory and learning. Ultimately, the work being done by Aptinyx with regards to NMDA receptors could potentially help with conditions like PTSD, Parkinson’s disease and dementia. Hence, it is easy to see why many investors might be a touch excited about the Aptinyx stock.
More importantly, two of the products from the company have already been awarded fast track approval from the United States Food and Drug Administration. One of those products is meant for the treatment of diabetic neuropathy and the other is for treating PTSD. Diabetic neuropathy commands a market of a staggering $11 billion at this point.
On the other hand, the market for PTSD products is also pretty big considering the fact that research suggests that one in 11 people could suffer from the condition at some point in their lifetimes. While it is true that those are two enormous markets, the possibility of cornering even a small portion of it could make Aptinyx a major player.
